Document is current
Any future updates will be listed below
-
Authors
Zhao, Yulei
Murciano-Goroff, Yonina R.
Xue, Jenny Y.
Ang, Agnes
Lucas, Jessica http://orcid.org/0000-0002-6462-7975
Mai, Trang T.
Da Cruz Paula, Arnaud F.
Saiki, Anne Y. http://orcid.org/0000-0003-3913-1860
Mohn, Deanna
Achanta, Pragathi
Sisk, Ann E.
Arora, Kanika S.
Roy, Rohan S.
Kim, Dongsung
Li, Chuanchuan
Lim, Lee P.
Li, Mark
Bahr, Amber
Loomis, Brian R. http://orcid.org/0000-0002-1863-1199
de Stanchina, Elisa
Reis-Filho, Jorge S. http://orcid.org/0000-0001-9927-1270
Weigelt, Britta http://orcid.org/0000-0003-2969-3173
Berger, Michael http://orcid.org/0000-0003-3882-5000
Riely, Gregory
Arbour, Kathryn C.
Lipford, J. Russell
Li, Bob T. http://orcid.org/0000-0001-6661-8733
Lito, Piro http://orcid.org/0000-0003-2196-3503
- License Information
-
More Information
Article History
Received: 1 March 2021
Accepted: 27 September 2021
First Online: 10 November 2021
Competing interests
: P.L. reports grants to his institution from Amgen, Mirati, Revolution Medicines, Boehringer Ingelheim and Virtec Pharmaceuticals; is listed as an inventor on patents filed by MSKCC on the treatment of BRAF-mutant or KRAS-mutant cancers; and reports consulting fees from Black Diamond Therapeutics, AmMax Bio, Repare Therapeutics and compensated scientific advisory board activity in Revolution Medicines and Boehringer Ingelheim. J.S.R.-F. reports receiving personal/consultancy fees from Goldman Sachs, REPARE Therapeutics, Paige.AI and Eli Lilly; holds membership of the scientific advisory boards of VolitionRx, REPARE Therapeutics and Paige.AI, membership of the Board of Directors of Grupo Oncoclinicas, and ad hoc membership of the scientific advisory boards of Roche Tissue Diagnostics, Ventana Medical Systems, Novartis, Genentech and InVicro, outside the scope of this study; and owns Paige.AI and REPARE Therapeutic stocks. Y.R.M.-G. received support for travel, accommodation and expenses from AstraZeneca. M.B. reports consulting fees from Roche and Eli Lilly. A.A., A.S., D.M., P.A. and J.R.L. are employees and shareholders of Amgen Inc. All other authors declare no competing interests.
